Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Padova, PD, Italy, 35128 was added as a study location and later removed. A Lancet Oncology publication reference for MIRASOL (with an Erratum) was added and later removed.
    Difference
    0.0%
    Check dated 2026-04-06T08:45:00.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-23T01:21:24.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    Publication citation updated: added Lancet Oncology 2025 paper on MIRASOL patient-reported outcomes with an erratum; the previous v3.4.2 citation was removed.
    Difference
    0.0%
    Check dated 2026-03-08T23:23:05.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Added Fallopian tube cancer as a listed condition on the study page and updated the page revision to v3.4.2.
    Difference
    0.0%
    Check dated 2026-02-15T14:26:12.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Minor site maintenance: Revision: v3.4.1 added and Revision: v3.4.0 removed; no effect on study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-08T05:24:43.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    This update adds a glossary toggle and updates certain metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted) and the revision to v3.4.0, with minor labeling adjustments for No FEAR Act data. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-24T00:21:58.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.